These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 29670617)

  • 1. Restoration of Decreased T Helper 1 and CD8+ T Cell Subsets Is Associated With Regression of Lymphoproliferative Disorders Developed During Methotrexate Treatment.
    Saito S; Suzuki K; Yoshimoto K; Kaneko Y; Yamaoka K; Shimizu T; Mori T; Okamoto S; Kameyama K; Amano K; Tamaru JI; Tokuhira M; Takeuchi T
    Front Immunol; 2018; 9():621. PubMed ID: 29670617
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Distinct patterns of lymphocyte count transition in lymphoproliferative disorder in patients with rheumatoid arthritis treated with methotrexate.
    Saito S; Kaneko Y; Yamaoka K; Tokuhira M; Takeuchi T
    Rheumatology (Oxford); 2017 Jun; 56(6):940-946. PubMed ID: 28165538
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Methotrexate/iatrogenic lymphoproliferative disorders in rheumatoid arthritis: histology, Epstein-Barr virus, and clonality are important predictors of disease progression and regression.
    Ichikawa A; Arakawa F; Kiyasu J; Sato K; Miyoshi H; Niino D; Kimura Y; Takeuchi M; Yoshida M; Ishibashi Y; Nakashima S; Sugita Y; Miura O; Ohshima K
    Eur J Haematol; 2013 Jul; 91(1):20-8. PubMed ID: 23560463
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD8(+) T-cell lymphoproliferative disorder associated with Epstein-Barr virus in a patient with rheumatoid arthritis during methotrexate therapy.
    Hatachi S; Kunitomi A; Aozasa K; Yagita M
    Mod Rheumatol; 2010 Oct; 20(5):500-5. PubMed ID: 20437072
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic factors of methotrexate-associated lymphoproliferative disorders associated with rheumatoid arthritis and plausible application of biological agents.
    Katsuyama T; Sada KE; Yan M; Zeggar S; Hiramatsu S; Miyawaki Y; Ohashi K; Morishita M; Watanabe H; Katsuyama E; Takano-Narazaki M; Toyota-Tatebe N; Sunahori-Watanabe K; Kawabata T; Miyake K; Kiguchi T; Wada J
    Mod Rheumatol; 2017 Sep; 27(5):773-777. PubMed ID: 27846761
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mature T/NK-cell lymphoproliferative disease and Epstein-Barr virus infection are more frequent in patients with rheumatoid arthritis treated with methotrexate.
    Kondo S; Tanimoto K; Yamada K; Yoshimoto G; Suematsu E; Fujisaki T; Oshiro Y; Tamura K; Takeshita M; Okamura S
    Virchows Arch; 2013 Apr; 462(4):399-407. PubMed ID: 23494713
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Methotrexate-associated lymphoproliferative disorder in the stomach and duodenum: a case report.
    Toyonaga H; Fukushima M; Shimeno N; Inokuma T
    BMC Gastroenterol; 2019 Apr; 19(1):62. PubMed ID: 31023238
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical characteristics of methotrexate-associated lymphoproliferative disorders: relationship between absolute lymphocyte count recovery and spontaneous regression.
    Takanashi S; Aisa Y; Ito C; Arakaki H; Osada Y; Amano Y; Hirano M; Nakazato T
    Rheumatol Int; 2017 Oct; 37(10):1629-1633. PubMed ID: 28676912
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical aspects in patients with rheumatoid arthritis complicated with lymphoproliferative disorders without regression after methotrexate withdrawal and treatment for arthritis after regression of lymphoproliferative disorders.
    Nakano K; Saito K; Nawata A; Hanami K; Kubo S; Miyagawa I; Fujino Y; Nakayamada S; Tanaka Y
    Mod Rheumatol; 2021 Jan; 31(1):94-100. PubMed ID: 32159414
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Methotrexate-related lymphoproliferative disorder of the lumbar spine origin presenting with severe low-back pain: case report.
    Kikuchi N; Uesugi M; Koda M; Shimizu T; Murakami K; Kono M; Tanaka H; Yamazaki M
    J Neurosurg Spine; 2018 Nov; 29(5):545-548. PubMed ID: 30168781
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Spontaneous regression of breast lymphoproliferative disorders after withdrawal of methotrexate in rheumatoid arthritis patients with Epstein-Barr virus infection: a case report and review of the literature.
    Ogawa A; Nakagawa T; Kumaki Y; Hosoya T; Oda G; Mori M; Fujioka T; Kubota K; Onishi I; Uetake H
    J Med Case Rep; 2022 Feb; 16(1):49. PubMed ID: 35125110
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lymphoproliferative disorders in rheumatoid arthritis: clinicopathological analysis of 76 cases in relation to methotrexate medication.
    Hoshida Y; Xu JX; Fujita S; Nakamichi I; Ikeda J; Tomita Y; Nakatsuka S; Tamaru J; Iizuka A; Takeuchi T; Aozasa K
    J Rheumatol; 2007 Feb; 34(2):322-31. PubMed ID: 17117491
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Primary cutaneous methotrexate-associated B-cell lymphoproliferative disorders other than EBV-positive mucocutaneous ulcer: clinical, pathological, and immunophenotypic features.
    Satou A; Banno S; Kohno K; Takahara T; Takahashi E; Nobata H; Iwagaitsu S; Watanabe D; Hanamura I; Takami A; Ito Y; Nakamura S; Tsuzuki T
    Pathology; 2021 Aug; 53(5):595-601. PubMed ID: 33618861
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune response in LPD during methotrexate administration (MTX-LPD) in rheumatoid arthritis patients.
    Saito S; Takeuchi T
    J Clin Exp Hematop; 2019; 59(4):145-155. PubMed ID: 31866617
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cessation of methotrexate and a small intestinal resection provide a good clinical course for a patient with a jejunum perforation induced by a methotrexate-associated lymphoproliferative disorder: a case report.
    Nomura M; Sumiya R; Ono H; Nagai T; Kumazawa K; Shimizu A; Endo D; Aoyanagi N
    World J Surg Oncol; 2021 Jan; 19(1):4. PubMed ID: 33388058
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Methotrexate-associated lymphoproliferative disorders of T-cell phenotype: clinicopathological analysis of 28 cases.
    Satou A; Tabata T; Miyoshi H; Kohno K; Suzuki Y; Yamashita D; Shimada K; Kawasaki T; Sato Y; Yoshino T; Ohshima K; Takahara T; Tsuzuki T; Nakamura S
    Mod Pathol; 2019 Jul; 32(8):1135-1146. PubMed ID: 30952973
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical characteristics and incidence of methotrexate-related lymphoproliferative disorders of patients with rheumatoid arthritis.
    Yoshida Y; Takahashi Y; Yamashita H; Kano T; Kaneko H; Mimori A
    Mod Rheumatol; 2014 Sep; 24(5):763-5. PubMed ID: 24498893
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Methotrexate-associated lymphoproliferative disorders mimicking angioimmunoblastic T-cell lymphoma.
    Hatanaka K; Nakamura N; Kojima M; Ando K; Irie S; Bunno M; Nakamine H; Uekusa T
    Pathol Res Pract; 2010 Jan; 206(1):9-13. PubMed ID: 19628340
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Primary hepatic methotrexate-associated lymphoproliferative disorder associated with Epstein-Barr virus reactivation and accompanied by spontaneous necrosis: A case report.
    Omameuda T; Miyato H; Sata N; Lefor AK
    Medicine (Baltimore); 2022 Nov; 101(47):e31993. PubMed ID: 36451467
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Methotrexate-associated Lymphoproliferative Disorders in Patients With Rheumatoid Arthritis: Clinicopathologic Features and Prognostic Factors.
    Kurita D; Miyoshi H; Ichikawa A; Kato K; Imaizumi Y; Seki R; Sato K; Sasaki Y; Kawamoto K; Shimono J; Yamada K; Muto R; Kizaki M; Nagafuji K; Tamaru JI; Tokuhira M; Ohshima K
    Am J Surg Pathol; 2019 Jul; 43(7):869-884. PubMed ID: 31116708
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.